Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Advanced Enzyme Technologies Ltd

| Statement Of Audited Consolidated Financial Results For The Quarter And Year Ended 31 March 20

Report Source

⬤9th May 26

Summary : Advanced Enzyme Technologies reports strong FY26 results, defers interim dividend for strategic growth, and makes key board appointments.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Consolidated Total Expenses: ₹5,594.12 million (FY26) vs. ₹4,825.87 million (FY25).
  2. Standalone Total Expenses: ₹3,546.22 million (FY26) vs. ₹2,923.73 million (FY25).
  3. Consolidated Revenue from operations: ₹7,457.57 million (FY26) vs. ₹6,369.10 million (FY25).
  4. Standalone Revenue from operations: ₹4,527.66 million (FY26) vs. ₹3,514.11 million (FY25).
  5. Consolidated Net cash generated from operating activities: ₹1,567.76 million (FY26) vs. ₹1,424.97 million (FY25).
  6. Consolidated Net cash used in investing activities: ₹(741.30) million (FY26) vs. ₹(891.01) million (FY25).
  7. Consolidated Net cash used in financing activities: ₹(703.66) million (FY26) vs. ₹(725.44) million (FY25).
  8. Standalone Net cash generated from operating activities: ₹887.31 million (FY26) vs. ₹634.79 million (FY25).
  9. Standalone Net cash used in investing activities: ₹(341.94) million (FY26) vs. ₹(17.38) million (FY25).
  10. Standalone Net cash used in financing activities: ₹(582.47) million (FY26) vs. ₹(576.32) million (FY25).
  11. Consolidated Total Assets: ₹18,387.61 million (FY26) vs. ₹16,213.47 million (FY25).
  12. Consolidated Total Equity: ₹16,831.22 million (FY26) vs. ₹14,686.70 million (FY25).
  13. Standalone Total Assets: ₹8,036.36 million (FY26) vs. ₹6,886.31 million (FY25).
  14. Standalone Total Equity: ₹7,096.23 million (FY26) vs. ₹6,293.41 million (FY25).
  15. Both standalone and consolidated financial results are presented and audited.

Corporate Overview

  1. Assessing financial impact of new labor codes.
  2. Manufacturing and sales of enzymes
  3. Cautious but forward-looking, preserving capital for strategic growth.
  4. Incorporated Advanced Nutrazyme Private Limited (ANPL) as a new wholly-owned subsidiary for sales and distribution of Nutrition and Wellness products.

Risk Factors

  1. Uncertainty from new labor codes.
  2. Interim dividend deferral impacts shareholders.
  3. Future strategic avenues carry risks.
  4. Regulatory changes could affect operations.

Key Drivers

  1. New subsidiary for wellness products.
  2. Capital preserved for strategic growth.
  3. Unmodified audit opinion received.
  4. Strong revenue and profit growth.

Auditor’s Report

  1. Unmodified opinion on both consolidated and standalone annual financial results.

Board Commentary

  1. Re-appointment of Mr. Mukund Madhusudan Kabra as Whole-time Director for 5 years (effective April 1, 2027).
  2. Appointment of Mr. Pradip Bhailal Shah as Additional Independent Director for 5 years (effective June 12, 2026).
  3. Recommended a Final Dividend @ 67.5% (₹1.35 per Equity Share) for FY 2025-26, subject to shareholder approval.
  4. Deferred declaration of an interim dividend to preserve capital for strategic avenues/corporate actions.
  5. Impact of new labor codes on remuneration structure and financial results.
  6. US court of appeals ruled in favor of Advanced Supplementary Technologies Corporation (subsidiary) in a lawsuit, leading to reversal of a provision.
  7. Government of India notified four new Labour Codes (Code on Wages, Industrial Relations Code, Social Security, Occupational Safety, Health and Working Conditions Code) in November 2025.
  8. Allotment of 49,350 Equity Shares under ESOP Scheme 2022, increasing paid-up share capital.
  9. Incorporation of Advanced Nutrazyme Private Limited (ANPL) as a new wholly-owned subsidiary (July 4, 2025) for Nutrition and Wellness product sales and distribution.

Corporate Governance

  1. Appointment of an Additional Independent Director, Mr. Pradip Bhailal Shah.
  2. Nomination and Remuneration Committee and Audit Committee are active in board recommendations.

Management Discussion & Analysis

Future Strategy

  1. Deferring interim dividend to preserve capital for potential strategic avenues/corporate actions to maximize long-term shareholder value.

Operational Focus Areas

  1. Monitoring finalization of Central/State Rules for new labor codes.

Performance Drivers

  1. Growth in consolidated and standalone revenue and profit for FY26.

Risk Control Measures

  1. Assessing impact of labor codes based on available information and guidance.

Critical Risks

  1. Incremental impact from changes in labor codes on remuneration structure.
Advanced Enzyme Technologies Ltd (ADVENZYMES) Quarterly Report Analysis & Insights | Dhanarthi